A Prospective, Single-Center, Single-Arm, Investigator-Initiated Exploratory Clinical Trial to Assess the Safety of Repetitive Transcranial Magnetic Stimulation for Children and Adolescents With Autism Spectrum Disorder

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-17
SponsorBundang CHA Hospital

About this trial

This is a prospective, single-center, single-arm, investigator-initiated exploratory clinical trial aimed at evaluating the safety and exploring the efficacy of a medical electromagnetic stimulator delivering low-frequency repetitive transcranial magnetic stimulation (rTMS) in children and adolescents with Autism Spectrum Disorder (ASD). ASD is a neurodevelopmental disorder characterized by deficits in social interaction and communication and restricted, repetitive behaviors. Despite increasing prevalence, effective treatment options remain limited, and the demand for non-invasive, safe interventions continues to grow.

In this study, a total of 18 participants aged 3 to 17 years with a clinical diagnosis of ASD will be enrolled. Participants will receive rTMS using a medically approved electromagnetic stimulator applied to the dorsolateral prefrontal cortex (DLPFC) - five sessions per week for two consecutive weeks (total of 10 sessions). The first 5 sessions will target the left DLPFC, and the remaining 5 will target the right DLPFC. Each session includes 18 trains of 10-second stimulations at 1Hz frequency with 20-second inter-train intervals. The stimulation intensity is set at 90% of the resting motor threshold (rMT), determined individually using motor evoked potential testing.

The primary objective of this trial is to assess the safety of low-frequency rTMS in this population, with adverse events such as seizures, headaches, dizziness, and mood changes monitored throughout the trial. Vital signs will also be checked before and after each session. Secondary objectives include exploratory evaluation of rTMS effects on sensory processing (SP), social communication (SCQ), autism severity (K-CARS), behavioral symptoms (CBCL), brain activity changes (fNIRS), and electrophysiological responses (EEG), assessed at baseline, immediately after intervention, and at 1- and 3-month follow-ups.

All participants will undergo baseline assessments including EEG, SP, SCQ, K-CARS, CBCL, fNIRS, and vital signs. These measures will be repeated after the final rTMS session, and again at 1 and 3 months post-intervention. The trial will be conducted at CHA Bundang Medical Center, led by Principal Investigator Professor Minyoung Kim, Department of Rehabilitation Medicine.

This exploratory study is designed to provide preliminary evidence for the safety of low-frequency rTMS in ASD and to gather pilot data on its potential therapeutic effects, which may support future randomized controlled trials and clinical applications.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged between 3 and 17 years at the time of enrollment

Clinically diagnosed with Autism Spectrum Disorder (ASD), including assessment using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)

Currently receiving outpatient care for ASD at the Department of Rehabilitation Medicine, CHA Bundang Medical Center

The participant and their legal guardian have been fully informed of the study and have voluntarily provided written informed consent

Disqualifiers

Diagnosed with a major neurological condition other than ASD

Epileptiform discharges detected on EEG screening requiring initiation or adjustment of antiepileptic medication

Diagnosed with other psychiatric disorders, such as schizophrenia or major depressive disorder

History of traumatic brain injury, brain tumor, or other significant brain conditions

Trial design

Design model

Single group

Treatments tested in this trial

  • Repetitive transcranial magentic stimulation

    Device

    Low frequencey repetitive transcranial magentic stimulation

Treatment groups

18 Participants
are divided into 1 treatment group
Group A: Repetitive transcranial magnetic stimulationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Incidence and Characteristics of Adverse Events Related to rTMS Treatment in Children and Adolescents with Autism Spectrum Disorder

This outcome measure assesses the safety of applying low-frequency repetitive transcranial magnetic stimulation (rTMS) using a medical electromagnetic stimulator in children and adolescents diagnosed with Autism Spectrum Disorder (ASD). All adverse events (AEs), including seizures, syncope, headaches, local pain, hearing problems, dizziness, mood disturbances, or other subjective discomforts, will be recorded during the study period. The severity and relationship of AEs to the intervention will be classified using standardized criteria (e.g., CTCAE v5.0). Vital signs will be monitored before and after each session to support safety evaluation.

Time frame
From baseline (Day 1) through end of follow-up at 3 months after the final rTMS session (approximately 90 days)

Secondary outcomes

1

Change in Sensory Profile (SP) Score

This outcome evaluates changes in sensory processing characteristics before and after the rTMS intervention using the Sensory Profile questionnaire. The aim is to explore whether low-frequency rTMS modulates sensory regulation in children and adolescents with ASD.

Time frame
Baseline (Day 1), Post-intervention (Day 12), 1-month follow-up (Day ~30), 3-month follow-up (Day ~90)
2

Change in Social Communication Questionnaire (SCQ) Score

This measure assesses changes in social communication behaviors following rTMS intervention. The SCQ evaluates communication skills and social functioning relevant to autism characteristics.

Time frame
Baseline (Day 1), Post-intervention (Day 12), 1-month follow-up (Day ~30), 3-month follow-up (Day ~90)
3

Change in Korean-Childhood Autism Rating Scale, 2nd Edition (K-CARS-2) Score

This outcome examines changes in autism severity by comparing K-CARS-2 scores across time points, investigating whether rTMS reduces core ASD symptoms.

Time frame
Baseline (Day 1), Post-intervention (Day 12), 3-month follow-up (Day ~90)
4

Change in Child Behavior Checklist (CBCL) Score

This measure explores changes in emotional and behavioral functioning post-rTMS, using the CBCL, a parent-reported instrument capturing internalizing and externalizing problems.

Time frame
Baseline (Day 1), Post-intervention (Day 12), 1-month follow-up (Day ~30), 3-month follow-up (Day ~90)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: